本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Evaxion Biotech A/S

3.58
+0.500016.23%
盤後3.630.0500+1.40%16:56 EDT
成交量:4.86萬
成交額:16.58萬
市值:2,972.37萬
市盈率:-3.58
高:3.65
開:3.08
低:3.08
收:3.08
52周最高:12.15
52周最低:1.20
股本:830.27萬
流通股本:553.19萬
量比:1.50
換手率:0.88%
股息:- -
股息率:- -
每股收益(TTM):-1.0000
每股收益(LYR):-1.0000
淨資產收益率:-100.18%
總資產收益率:-28.23%
市淨率:1.74
市盈率(LYR):-3.58

資料載入中...

2026/03/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/11/21

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/04/01

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/21

SEC問詢函

Form CORRESP - Correspondence
2025/01/29

SEC問詢函

Form CORRESP - Correspondence
2025/01/28

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/12/18

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/12/05

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/11/18

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/11/14

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/07

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/20

SEC問詢函

Form CORRESP - Correspondence
2024/08/20

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/07/22

SEC問詢函

Form CORRESP - Correspondence
2024/07/22

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/05/06

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/03/26

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/31

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/01/31

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/01/30

SEC問詢函

Form CORRESP - Correspondence